Generation of HIV-1 potent and broad neutralizing antibodies by immunization with postfusion HR1/HR2 complex

AIDS

Volumn 27, Issue 5, 2013, Pages 717-730

  Dawood, Reham ^a   Benjelloun, Fahd ^a   Pin, Jean J ^b   Kone, Amadou ^a   Chanut, Blandine ^a   Jospin, Fabienne ^a   Lucht, Frederic ^a   Verrier, Bernard ^c   Moog, Christaine ^d   Genin, Christain ^a   Paul, Stéphane ^a  

^a UNIVERSITÉ JEAN MONNET   (France)

^b DENDRITICS SAS   (France)

^c INSTITUT DE BIOLOGIE ET CHIMIE DES PROTÉINES   (France)

^d Institute of Virology   (France)

Author keywords

Antibody; Fusion complex; Gp41; Heptad repeat regions 1 heptad repeat regions 2; Neutralization

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 140; HEPTAD REPEAT REGION 1 HEPTAD REPEAT REGION 2 COMPLEX; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; B LYMPHOCYTE; CELL FUSION; CELLULAR IMMUNITY; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOREACTIVITY; IMMUNOSTIMULATION; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SYNCYTIUM; VACCINATION; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; MEMBRANE GLYCOPROTEINS; MICE; PROTEIN STRUCTURE, SECONDARY; REPETITIVE SEQUENCES, NUCLEIC ACID; TRANSFECTION; VACCINATION; VIRAL ENVELOPE PROTEINS;

EID: 84876375560     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835cfca5     Document Type: Article

References (69)

1. Walker BD, Ahmed R, Plotkin S. Moving ahead an HIV vaccine: use both arms to beat HIV. Nat Med 2011; 17:1194-1195.
2. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 2012; 12:396-407.
3. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477:466-470.
4. Buonaguro L, Tornesello ML, Buonaguro FM. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol 2007; 81:10209-10219.
5. Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 2010; 22:358-366.
6. Harrison SC. Viral membrane fusion. Nat Struct Mol Biol 2008; 15:690-698.
7. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984; 312:763-767.
8. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984; 312:767- 768.
9. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005; 310:1025-1028.
10. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17:657-700.
11. Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol 1997; 9:551-562.
12. Weissenhorn W, Hinz A, Gaudin Y. Virus membrane fusion. FEBS Lett 2007; 581:2150-2155.
13. Munoz-Barroso I, Durell S, Sakaguchi K, Appella E, Blumenthal R. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol 1998; 140:315- 323.
14. Furuta RA, Wild CT, Weng Y, Weiss CD. Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 1998; 5:276-279.
15. Matthews T, Salgo M, Greenberg M, Chung J, De Masi R, Bolognesi D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 2004; 3:215-225.
16. Caffrey M, Cai M, Kaufman J, Stahl SJ, Wingfield PT, Covell DG, et al. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J 1998; 17:4572-4584.
17. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89:263-273.
18. Lu M, Blacklow SC, Kim PS. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995; 2:1075-1082.
19. Buzon V, Natrajan G, Schibli D, Campelo F, Kozlov MM, Weissenhorn W. Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog 2010; 6:e1000880.
20. Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, Cohen FS. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 2000; 151:413-423.
21. Weissenhorn W, Calder LJ, Dessen A, Laue T, Skehel JJ, Wiley DC. Assembly of a rod-shaped chimera of a trimeric GCN4 zipper and the HIV-1 gp41 ectodomain expressed in Escherichia coli. Proc Natl Acad Sci U S A 1997; 94:6065- 6069.
22. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997; 387:426-430.
23. de Rosny E, Vassell R, Jiang S, Kunert R, Weiss CD. Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol 2004; 78:2627-2631.
24. Dimitrov AS, Jacobs A, Finnegan CM, Stiegler G, Katinger H, Blumenthal R. Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein- mediated fusion. Biochemistry 2007; 46:1398-1401.
25. Frey G, Peng H, Rits-Volloch S, Morelli M, Cheng Y, Chen B. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci U S A 2008; 105:3739-3744.
26. Barbato G, Bianchi E, Ingallinella P, Hurni WH, Miller MD, Ciliberto G, et al. Structural analysis of the epitope of the anti- HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J Mol Biol 2003; 330:1101-1115.
27. Brunel FM, Zwick MB, Cardoso RM, Nelson JD, Wilson IA, Burton DR, Dawson PE. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J Virol 2006; 80:1680- 1687.
28. Cardoso RM, Brunel FM, Ferguson S, Zwick M, Burton DR, Dawson PE, Wilson IA. Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. J Mol Biol 2007; 365:1533-1544.
29. Law M, Cardoso RM, Wilson IA, Burton DR. Antigenic and immunogenic study of membrane-proximal external regiongrafted gp120 antigens by a DNA prime-protein boost immunization strategy. J Virol 2007; 81:4272-4285.
30. McGaughey GB, Citron M, Danzeisen RC, Freidinger RM, Garsky VM, Hurni WM, et al. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. Biochemistry 2003; 42:3214- 3223.
31. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993; 67:6642-6647.
32. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001; 75:10892- 10905.
33. Chen YH, Bock G, Vornhagen R, Steindl F, Katinger H, Dierich MP. HIV-1 gp41 binding proteins and antibodies to gp41 could inhibit enhancement of human Raji cell MHC class I and II expression by gp41. Mol Immunol 1994; 31:977-982.
34. Morris L, Chen X, Alam M, Tomaras G, Zhang R, Marshall DJ, et al. Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One 2011; 6:e23532.
35. Montero M, Gulzar N, Klaric KA, Donald JE, Lepik C, Wu S, et al. Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane. J Virol 2012; 86:2930- 2941.
36. Vincent N, Kone A, Chanut B, Lucht F, Genin C, Malvoisin E. Antibodies purified from sera of HIV-1-infected patients by affinity on the heptad repeat region 1/heptad repeat region 2 complex of gp41 neutralize HIV-1 primary isolates. AIDS 2008; 22:2075-2085.
37. Jiang S, Lin K, Lu M. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J Virol 1998; 72:10213-10217.
38. Bianchi E, Finotto M, Ingallinella P, Hrin R, Carella AV, Hou XS, et al. Covalent stabilization of coiled coils of the HIV gp41N region yields extremely potent and broad inhibitors of viral infection. Proc Natl Acad Sci U S A 2005; 102:12903-12908.
39. Nelson JD, Kinkead H, Brunel FM, Leaman D, Jensen R, Louis JM, et al. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but nonneutralizing antibodies also bind to NHR mimetics. Virology 2008; 377:170-183.
40. Louis JM, Nesheiwat I, Chang L, Clore GM, Bewley CA. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J Biol Chem 2003; 278:20278-20285.
41. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One; 5:e8805.
42. Sabin C, Corti D, Buzon V, Seaman MS, Lutje Hulsik D, Hinz A, et al. Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41. PLoS Pathog 2010; 6:e1001195.
43. Bianchi E, Joyce JG, Miller MD, Finnefrock AC, Liang X, Finotto M, et al. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci U S A 2010; 107:10655-10660.
44. de Rosny E, Vassell R, Wingfield PT, Wild CT, Weiss CD. Peptides corresponding to the heptad repeat motifs in the transmembrane protein (gp41) of human immunodeficiency virus type 1 elicit antibodies to receptor-activated conformations of the envelope glycoprotein. J Virol 2001; 75:8859- 8863.
45. Golding H, Zaitseva M, de Rosny E, King LR, Manischewitz J, Sidorov I, et al. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J Virol 2002; 76:6780-6790.
46. Gustchina E, Li M, Louis JM, Anderson DE, Lloyd J, Frisch C, et al. Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41. PLoS Pathog 2010; 6:e1001182.
47. Trebak M, Chong JM, Herlyn D, Speicher DW. Efficient laboratory- scale production of monoclonal antibodies using membrane- based high-density cell culture technology. J Immunol Methods 1999; 230:59-70.
48. Fenyo EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, et al. International network for comparison of HIV neutralization assays: the Neut Net report. PLoS One 2009; 4:e4505.
49. Holl V, Peressin M, Schmidt S, Decoville T, Zolla-Pazner S, Aubertin AM, Moog C. Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation. Blood 2006; 107:4466-4474.
50. Welch BD, VanDemark AP, Heroux A, Hill CP, Kay MS. Potent D-peptide inhibitors of HIV-1 entry. Proc Natl Acad Sci U S A 2007; 104:16828-16833.
51. Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 2006; 24:739-769.
52. Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 2004; 54:333- 340.
53. Moyle G. Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART. J Antimicrob Chemother 2003; 51:213- 217.
54. McGaughey GB, Barbato G, Bianchi E, Freidinger RM, Garsky VM, Hurni WM, et al. Progress towards the development of a HIV-1 gp41-directed vaccine. Curr HIV Res 2004; 2:193-204.
55. Poveda E, Briz V, Soriano V. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev 2005; 7:139-147.
56. Xu JY, Gorny MK, Palker T, Karwowska S, Zolla-Pazner S. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol 1991; 65:4832-4838.
57. Pietzsch J, Scheid JF, Mouquet H, Seaman MS, Broder CC, Nussenzweig MC. Antigp41 antibodies cloned from HIVinfected patients with broadly neutralizing serologic activity. J Virol 2010; 84:5032-5042.
58. Gauduin MC, Parren PW, Weir R, Barbas CF, Burton DR, Koup RA. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 1997; 3:1389-1393.
59. Xu W, Hofmann-Lehmann R, McClure HM, Ruprecht RM. Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV. Vaccine 2002; 20:1956-1960.
60. Chen CH, Greenberg ML, Bolognesi DP, Matthews TJ. Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41. AIDS Res Hum Retroviruses 2000; 16:2037- 2041.
61. Diomede L, Nyoka S, Pastori C, Scotti L, Zambon A, Sherman G, et al. Passively transmitted gp41 antibodies in babies born from subtype C HIV-1 seropositive women: correlation between fine specificity and protection. J Virol 2012; 86:4129- 4138.
62. Dimitrov AS, Louis JM, Bewley CA, Clore GM, Blumenthal R. Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation. Biochemistry 2005; 44:12471-12479.
63. Hartono YD, Lazim R, Yip YM, Zhang D. Computational study of bindings of HK20 Fab and D5 Fab to HIV-1 gp41. Bioorg Med Chem Lett 2012; 22:1695-1700.
64. Jin L, Pan C, Qi Z, Zhou ZH, Jiang S. Fab crystallization and preliminary X-ray analysis of NC-1, an anti-HIV-1 antibody that recognizes the six-helix bundle core of gp41. Acta Crystallogr Sect F Struct Biol Cryst Commun 2010; 66:854-857.
65. Luftig MA, Mattu M, Di Giovine P, Geleziunas R, Hrin R, Barbato G, et al. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate- directed antibody. Nat Struct Mol Biol 2006; 13:740-747.
66. Miller MD, Geleziunas R, Bianchi E, Lennard S, Hrin R, Zhang H, et al. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A 2005; 102:14759-14764.
67. Bellamy-McIntyre AK, Lay CS, Baar S, Maerz AL, Talbo GH, Drummer HE, Poumbourios P. Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion. J Biol Chem 2007; 282:23104-23116.
68. Fiebig U, Schmolke M, Eschricht M, Kurth R, Denner J. Mode of interaction between the HIV-1-neutralizing monoclonal antibody 2F5 and its epitope. AIDS 2009; 23:887-895.
69. Massanella M, Puigdomenech I, Cabrera C, Fernandez-Figueras MT, Aucher A, Gaibelet G, et al. Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells. AIDS 2009; 23:183-188.